Tag: adults

Lilly’s SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
June 5, 2022

Lilly’s SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight

Detailed results from Lilly’s first phase 3 trial in obesity or overweight presented at the American Diabetes Association’s® 82nd Scientific Sessions® and simultaneously published in NEJM INDIANAPOLIS, June 4, 2022 /PRNewswire/ — Detailed results from Eli Lilly and Company’s (NYSE: LLY) phase 3 SURMOUNT-1 clinical trial evaluating tirzepatide for the treatment of obesity or overweight were simultaneously published today in The New …
Full Article
Cat’s Meow: Robotic Pet Boosts Mood, Cognition in Adults with Dementia
November 17, 2021

Cat’s Meow: Robotic Pet Boosts Mood, Cognition in Adults with Dementia

Study participants smiled and talked to their robotic cats and expressed feelings such as “The cat looks at me like someone who listens to me and loves me”. People with Alzheimer’s disease or related dementia (ADRD) often experience behavioral and psychological symptoms such as depression, aggression, and anxiety. Often these symptoms are treated with antipsychotics, antidepressants, and benzodiazepines, which often …
Full Article
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults | Small Molecules
October 12, 2021

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults | Small Molecules

Merck and Ridgeback announce the filing of an emergency filing with the U.S. FDA for molnupiravir, an investigational oral antiviral drug used to treat mild to moderate COVID-19 in at-risk adults Details Category: Small Molecules Posted on Monday, October 11, 2021 6:43 PM Hits: 210 If approved, molnupiravir could become the first oral antiviral drug to treat COVID-19. be Filings …
Full Article
Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults
October 11, 2021

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

KENILWORTH, NJ & MIAMI–(GESCHÄFTSDRAHT)–Merck (NYSE: MRK), außerhalb der Vereinigten Staaten und Kanadas als MSD bekannt, und Ridgeback Biotherapeutics gaben heute bekannt, dass Merck bei der US-amerikanischen Food and Drug Administration (FDA) einen Zulassungsantrag für den Notfall (EUA) für Molnupiravir eingereicht hat. ein orales antivirales Prüfarzneimittel zur Behandlung von leichtem bis mittelschwerem COVID-19 bei Erwachsenen, bei denen das Risiko besteht, zu …
Full Article